23 results on '"Souleymane, Mahamadou Bassirou"'
Search Results
2. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
- Author
-
Souleymane, Mahamadou Bassirou, Decroo, Tom, Soumana, Alphazazi, Maman Lawan, Ibrahim, Gagara-Issoufou, Assiatou, Halidou-Moussa, Souleymane, Ortuño-Gutiérrez, Nimer, Adehossi, Eric, Mamadou, Saïdou, Van Deun, Armand, and Piubello, Alberto
- Published
- 2022
- Full Text
- View/download PDF
3. Pre-treatment Loss to Follow-up in Patients with Confirmed Pulmonary Tuberculosis in Niamey, Niger
- Author
-
Madougou, Assiatou Gagara Issoufou, primary, Souleymane, Mahamadou Bassirou, additional, Soumana, Alphazazi, additional, and Moussa, Souleymane Halidou, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Pre-Treatment Loss to Follow-up of Patients with Bacilloscopy-Confirmed Pulmonary Tuberculosis in the National Center for the Fight Against Tuberculosis and Respiratory Diseases in Niamey
- Author
-
Madougou, Assiatou Gagara Issoufou, primary, Souleymane, Mahamadou Bassirou, additional, Soumana, Alphazazi, additional, and Moussa, Souleymane Halidou, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family
- Author
-
Ejo, Mebrat, Hassane-Harouna, Souleymane, Souleymane, Mahamadou Bassirou, Lempens, Pauline, Dockx, Jeroen, Uwizeye, Cecile, De Rijk, Pim, Decroo, Tom, Diro, Ermias, Torrea, Gabriela, Rigouts, Leen, Piubello, Alberto, and de Jong, Bouke C.
- Published
- 2020
- Full Text
- View/download PDF
6. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements
- Author
-
Piubello, Alberto, Souleymane, Mahamadou Bassirou, Hassane-Harouna, Souleymane, Yacouba, Abdourahamane, Lempens, Pauline, Assao-Neino, Mourtala Mohamed, Maman-Lawan, Ibrahim, Attaher, Sala, Moustapha, Boubacar, Soumana, Alphazazi, Gagara-Issoufou, Assiatou, Ortuño-Gutiérrez, Nimer, Roggi, Alberto, Gumusboga, Mourad, Hamidou-Harouna, Zelika, Dockx, Jeroen, Mamadou, Saïdou, de Jong, Bouke C., Decroo, Tom, and Van Deun, Armand
- Published
- 2020
- Full Text
- View/download PDF
7. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020
- Author
-
Migliori, Giovanni Battista, Thong, Pei Min, Akkerman, Onno, Alffenaar, Jan-Willem, Alvarez-Navascues, Fernando, Assao-Neino, Mourtala Mohamed, Bernard, Pascale Valerie, Biala, Joshua Sorba, Blanc, Francois-Xavier, Bogorodskaya, Elena M., Borisov, Sergey, Buonsenso, Danilo, Calnan, Marianne, Castellotti, Paola Francesca, Centis, Rosella, Chakaya, Jeremiah Muhwa, Cho, Jin-Gun, Codecasa, Luigi Ruffo, D'Ambrosio, Lia, Denholm, Justin, Enwerem, Martin, Ferrarese, Maurizio, Galvao, Tatiana, Garcia-Clemente, Maria, Garcia-Garcia, Jose-Maria, Gualano, Gina, Gullon-Blanco, Jose Antonio, Inwentarz, Sandra, Ippolito, Giuseppe, Kunst, Heinke, Maryandyshev, Andrei, Melazzini, Mario, Mello, Fernanda Carvalho de Queiroz, Munoz-Torrico, Marcela, Njungfiyini, Patrick Bung, Palmero, Domingo Juan, Palmieri, Fabrizio, Piccioni, Pavilio, Piubello, Alberto, Rendon, Adrian, Sabria, Josefina, Saporiti, Matteo, Scognamiglio, Paola, Sharma, Samridhi, Silva, Denise Rossato, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Tabernero, Eva, Tadolini, Marina, Tchangou, Michel Eke, Thornton, Alice Boi Yatta, Tiberi, Simon, Udwadia, Zarir F., Sotgiu, Giovanni, Ong, Catherine Wei Min, and Goletti, Delia
- Subjects
Ambulatory care facilities -- Statistics -- Safety and security measures -- International aspects ,Tuberculosis -- Statistics -- Care and treatment -- International aspects ,COVID-19 -- International aspects -- Influence ,Health - Abstract
The coronavirus disease (COVID-19) pandemic has affected clinical management of tuberculosis (TB) and TB-related services (2,2). Reports of the first cohorts of patients with COVID-19 and TB have been recently [...]
- Published
- 2020
- Full Text
- View/download PDF
8. Evaluating the Effectiveness of a Novel Systematic Screening Approach for Tuberculosis among Individuals Suspected or Recovered from COVID-19: Experiences from Niger and Guinea
- Author
-
Aboubacar Sidiki Magassouba, Souleymane Mahamadou Bassirou, Almamy Amara Touré, Boubacar Djelo Diallo, Soumana Alphazazi, Diao Cissé, Mohamed Sitan Keita, Elhadj Saidou Seyabatou, Adama Marie Bangoura, Hugues Asken Traoré, Tom Decroo, Jonathon R. Campbell, Vanessa Veronese, and Corinne Simone Collette Merle
- Subjects
COVID-19 ,tuberculosis ,active TB screening ,Guinea ,Niger ,Medicine - Abstract
Evidence suggests that the COVID-19 pandemic negatively impacts tuberculosis (TB) activities. As TB and COVID-19 have similar symptoms, we assessed the effectiveness of integrated TB/COVID-19 screening in Guinea and Niger. From May to December 2020, TB screening was offered to symptomatic patients after a negative COVID-19 PCR test or after recovery from COVID-19 in Guinea. From December 2020 to March 2021, all presumptive COVID-19 patients with respiratory symptoms were tested simultaneously for COVID-19 and TB in Niger. We assessed the TB detection yield and used micro-costing to estimate the costs associated with both screening algorithms. A total of 863 individuals (758 in Guinea, and 105 in Niger), who were mostly male (60%) and with a median age of 34 (IQR: 26–45), were screened for TB. Reported symptoms were cough ≥2 weeks (49%), fever (45%), and weight loss (30%). Overall, 61 patients (7%) tested positive for COVID-19 (13 in Guinea, 48 in Niger) and 43 (4.9%) were diagnosed with TB disease (35 or 4.6% in Guinea, and 8 or 7.6% in Niger). The cost per person initiating TB treatment was USD $367 in Guinea and $566 in Niger. Overall, the yield of both approaches was high, and the cost was modest. Optimizing integrated COVID-19/TB screening may support maintaining TB detection during the ongoing pandemic.
- Published
- 2022
- Full Text
- View/download PDF
9. High rate of adverse drug reactions with a novel tuberculosis retreatment regimen combining triple-doses of both isoniazid and rifampicin
- Author
-
Souleymane, Mahamadou Bassirou, primary, Kadri, Sani, additional, Piubello, Alberto, additional, Tsoumanis, Achilleas, additional, Soumana, Alphazazi, additional, Issa, Hamidou, additional, Amoussa, Abdoulaziz Kabirou, additional, Van Deun, Armand, additional, Lynen, Lutgarde, additional, de Jong, Bouke Catherine, additional, and Decroo, Tom, additional
- Published
- 2023
- Full Text
- View/download PDF
10. High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin
- Author
-
Souleymane, Mahamadou Bassirou, Kadri, Sani, Piubello, Alberto, Tsoumanis, Achilleas, Soumana, Alphazazi, Issa, Hamidou, Amoussa, Abdoulaziz Kabirou, Van Deun, Armand, Lynen, Lutgarde, de Jong, Bouke Catherine, and Decroo, Tom
- Published
- 2023
- Full Text
- View/download PDF
11. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
- Author
-
Souleymane, Mahamadou Bassirou, Decroo, Tom, Mamadou, Saïdou, Soumana, Alphazazi, Lawan, Ibrahim Mamane, Gagara-Issoufou, Assiatou, Adehossi, Eric, Ortuño-Gutiérrez, Nimer, Lynen, Lutgarde, Rigouts, Leen, Jong, Bouke Catherine de, Deun, Armand Van, and Piubello, Alberto
- Subjects
- *
TUBERCULOSIS patients , *TREATMENT effectiveness , *COHORT analysis , *TREATMENT failure , *RETROSPECTIVE studies - Abstract
Background Outcomes of retreatment for rifampicin-resistant tuberculosis (RR-TB) are rarely reported. We report 'definitive outcomes' after a cascade approach to RR-TB treatment. After a bacteriologically adverse outcome for the 9-months fluoroquinolone-based Short Treatment Regimen (STR), patients were retreated with a bedaquiline-based regimen (BDQ-regimen). Methods A Retrospective cohort study of RR-TB patients treated with the STR during 2012–2019 and retreated with a BDQ-regimen in case of failure or relapse was conducted. Definitive relapse-free cure took into account BDQ-regimen outcomes. Results Of 367 patients treated with the STR, 20 (5.4%) experienced failure or relapse. Out of these 20 patients, 14 started a BDQ-regimen, of whom none experienced failure or relapse. Definitive end of treatment outcomes of STR after revising with third-line BDQ-regimen outcomes, 84.7% (311/367) were cured relapse-free, 10.6% (39/367) died during treatment and 3.0% (11/367) were lost to follow-up during treatment with either the STR or BDQ-regimen. Six patients (1.6%; 6/367) with STR failure/relapse died before starting a BDQ-regimen. No patient had definitive treatment failure or relapse and remained without treatment. Conclusions If fluoroquinolone resistance is excluded or rare, it is beneficial to use fluoroquinolone as the core drug for a first RR-TB treatment regimen and to safeguard bedaquiline for those in need of retreatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
- Author
-
Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista
- Published
- 2021
13. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
- Author
-
Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan-Willem, Al-Marzouqi, Nada Hassan, Arias-Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey E., Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García-García, José-María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska-Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado-Laborín, Rafael, Li, Yang, Magis-Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Munoz-Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie-Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo
- Published
- 2019
- Full Text
- View/download PDF
14. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss
- Author
-
Souleymane, Mahamadou Bassirou, primary, Piubello, Alberto, additional, Lawan, Ibrahim Mamane, additional, Hassane-Harouna, Souleymane, additional, Assao-Neino, Mourtala Mohamed, additional, Soumana, Alphazazi, additional, Hamidou-Harouna, Zelika, additional, Gagara-Issoufou, Assiatou, additional, Ortuño-Gutiérrez, Nimer, additional, Roggi, Alberto, additional, Schwoebel, Valerie, additional, Mamadou, Saïdou, additional, Lynen, Lutgarde, additional, De Jong, Bouke, additional, Van Deun, Armand, additional, and Decroo, Tom, additional
- Published
- 2020
- Full Text
- View/download PDF
15. High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
- Author
-
Decroo, Tom, primary, de Jong, Bouke C., additional, Piubello, Alberto, additional, Souleymane, Mahamadou Bassirou, additional, Lynen, Lutgarde, additional, and Van Deun, Armand, additional
- Published
- 2020
- Full Text
- View/download PDF
16. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis
- Author
-
Abidi, Syed, primary, Achar, Jay, additional, Assao Neino, Mourtala Mohamed, additional, Bang, Didi, additional, Benedetti, Andrea, additional, Brode, Sarah, additional, Campbell, Jonathon R., additional, Casas, Esther C., additional, Conradie, Francesca, additional, Dravniece, Gunta, additional, du Cros, Philipp, additional, Falzon, Dennis, additional, Jaramillo, Ernesto, additional, Kuaban, Christopher, additional, Lan, Zhiyi, additional, Lange, Christoph, additional, Li, Pei Zhi, additional, Makhmudova, Mavluda, additional, Maug, Aung Kya Jai, additional, Menzies, Dick, additional, Migliori, Giovanni Battista, additional, Miller, Ann, additional, Myrzaliev, Bakyt, additional, Ndjeka, Norbert, additional, Noeske, Jürgen, additional, Parpieva, Nargiza, additional, Piubello, Alberto, additional, Schwoebel, Valérie, additional, Sikhondze, Welile, additional, Singla, Rupak, additional, Souleymane, Mahamadou Bassirou, additional, Trébucq, Arnaud, additional, Van Deun, Armand, additional, Viney, Kerri, additional, Weyer, Karin, additional, Zhang, Betty Jingxuan, additional, and Ahmad Khan, Faiz, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
- Author
-
Borisov, Sergey, primary, Danila, Edvardas, additional, Maryandyshev, Andrei, additional, Dalcolmo, Margareth, additional, Miliauskas, Skaidrius, additional, Kuksa, Liga, additional, Manga, Selene, additional, Skrahina, Alena, additional, Diktanas, Saulius, additional, Codecasa, Luigi Ruffo, additional, Aleksa, Alena, additional, Bruchfeld, Judith, additional, Koleva, Antoniya, additional, Piubello, Alberto, additional, Udwadia, Zarir Farokh, additional, Akkerman, Onno W., additional, Belilovski, Evgeny, additional, Bernal, Enrique, additional, Boeree, Martin J., additional, Cadiñanos Loidi, Julen, additional, Cai, Qingshan, additional, Cebrian Gallardo, Jose Joaquín, additional, Dara, Masoud, additional, Davidavičienė, Edita, additional, Forsman, Lina Davies, additional, De Los Rios, Jorge, additional, Denholm, Justin, additional, Drakšienė, Jacinta, additional, Duarte, Raquel, additional, Elamin, Seifeldin Eltaeb, additional, Escobar Salinas, Nadia, additional, Ferrarese, Maurizio, additional, Filippov, Alexey, additional, Garcia, Ana, additional, García-García, José-María, additional, Gaudiesiute, Ieva, additional, Gavazova, Blagovesta, additional, Gayoso, Regina, additional, Gomez Rosso, Roscio, additional, Gruslys, Vygantas, additional, Gualano, Gina, additional, Hoefsloot, Wouter, additional, Jonsson, Jerker, additional, Khimova, Elena, additional, Kunst, Heinke, additional, Laniado-Laborín, Rafael, additional, Li, Yang, additional, Magis-Escurra, Cecile, additional, Manfrin, Vinicio, additional, Marchese, Valentina, additional, Martínez Robles, Elena, additional, Matteelli, Alberto, additional, Mazza-Stalder, Jesica, additional, Moschos, Charalampos, additional, Muñoz-Torrico, Marcela, additional, Mustafa Hamdan, Hamdan, additional, Nakčerienė, Birutė, additional, Nicod, Laurent, additional, Nieto Marcos, Magnolia, additional, Palmero, Domingo Juan, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Pontarelli, Agostina, additional, Quirós, Sarai, additional, Rendon, Adrian, additional, Saderi, Laura, additional, Šmite, Agnese, additional, Solovic, Ivan, additional, Souleymane, Mahamadou Bassirou, additional, Tadolini, Marina, additional, van den Boom, Martin, additional, Vescovo, Marisa, additional, Viggiani, Pietro, additional, Yedilbayev, Askar, additional, Zablockis, Rolandas, additional, Zhurkin, Dmitry, additional, Zignol, Matteo, additional, Visca, Dina, additional, Spanevello, Antonio, additional, Caminero, José A., additional, Alffenaar, Jan-Willem, additional, Tiberi, Simon, additional, Centis, Rosella, additional, D'Ambrosio, Lia, additional, Pontali, Emanuele, additional, Sotgiu, Giovanni, additional, and Migliori, Giovanni Battista, additional
- Published
- 2019
- Full Text
- View/download PDF
18. Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study
- Author
-
Giovanni Battista Migliori1, Pei Min Thong2, Jan-Willem Alffenaar3,4,5, Justin Denholm6,7, Marina Tadolini8,9, Fatma Alyaquobi10, Seif Al-Abri11, François-Xavier Blanc12, Danilo Buonsenso13, Jeremiah Chakaya14,15, Jin-Gun Cho4,16, Luigi Ruffo Codecasa17, Edvardas Danila18, Raquel Duarte19, Rada Dukpa20, José-María García-García21, Gina Gualano22, Xhevat Kurhasani23,24, Katerina Manika25, Fernanda Carvalho de Queiroz Mello26, Kristin Pahl27, Adrian Rendon28, Giovanni Sotgiu29, Mahamadou Bassirou Souleymane30, Tania A. Thomas31, Simon Tiberi32,33, Heinke Kunst32,33, Zarir F. Udwadia34, Delia Goletti22, Rosella Centis1, Lia D’Ambrosio35, Denise Rossato Silva36, Migliori, Giovanni Battista, Thong, Pei Min, Alffenaar, Jan-Willem, Denholm, Justin, Tadolini, Marina, Alyaquobi, Fatma, Al-Abri, Seif, Blanc, François-Xavier, Buonsenso, Danilo, Chakaya, Jeremiah, Cho, Jin-Gun, Codecasa, Luigi Ruffo, Danila, Edvarda, Duarte, Raquel, Dukpa, Rada, García-García, José-María, Gualano, Gina, Kurhasani, Xhevat, Manika, Katerina, Mello, Fernanda Carvalho de Queiroz, Pahl, Kristin, Rendon, Adrian, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Thomas, Tania A, Tiberi, Simon, Kunst, Heinke, Udwadia, Zarir F, Goletti, Delia, Centis, Rosella, D'Ambrosio, Lia, and Silva, Denise Rossato
- Subjects
Coronavirus ,wa_30 ,Pandemic ,wc_506 ,Communicable Disease Control ,Influenza, Human ,Humans ,COVID-19 ,Tuberculosis ,wf_200 ,Pandemics ,Human - Abstract
The objective of this study was to describe country-specific lockdown measures and tuberculosis indicators collected during the first year of the COVID-19 pandemic. Data on lockdown/social restrictions (compulsory face masks and hand hygiene; international and local travel restrictions; restrictions to family visits, and school closures) were collected from 24 countries spanning five continents. The majority of the countries implemented multiple lockdowns with partial or full reopening. There was an overall decrease in active tuberculosis, drug-resistant tuberculosis, and latent tuberculosis cases. Although national lockdowns were effective in containing COVID-19 cases, several indicators of tuberculosis were affected during the pandemic.
- Published
- 2022
19. Impact of COVID-19 on diagnosis of tuberculosis and tuberculosis infection in South America, Asia, and Africa.
- Author
-
Silva DR, Centis R, D'Ambrosio L, Mello FCQ, Pereira GR, Aguirre S, Al-Abri S, Al-Thohli K, Yaquobi FA, Calnan M, Teixeira RC, Inwentarz S, Palmero DJ, Piubello A, Sharma S, Souleymane MB, Soumana A, Tham SM, Thong PM, Udwadia ZF, Boom MVD, Sotgiu G, and Migliori GB
- Subjects
- Humans, South America epidemiology, Africa epidemiology, Asia epidemiology, Pandemics, COVID-19 epidemiology, Tuberculosis diagnosis, Tuberculosis epidemiology, SARS-CoV-2
- Published
- 2024
- Full Text
- View/download PDF
20. Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study.
- Author
-
Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaquobi F, Al-Abri S, Blanc FX, Buonsenso D, Chakaya J, Cho JG, Codecasa LR, Danila E, Duarte R, Dukpa R, García-García JM, Gualano G, Kurhasani X, Manika K, Mello FCQ, Pahl K, Rendon A, Sotgiu G, Souleymane MB, Thomas TA, Tiberi S, Kunst H, Udwadia ZF, Goletti D, Centis R, D'Ambrosio L, and Silva DR
- Subjects
- Communicable Disease Control, Humans, Pandemics prevention & control, COVID-19 epidemiology, COVID-19 prevention & control, Influenza, Human epidemiology, Tuberculosis
- Abstract
The objective of this study was to describe country-specific lockdown measures and tuberculosis indicators collected during the first year of the COVID-19 pandemic. Data on lockdown/social restrictions (compulsory face masks and hand hygiene; international and local travel restrictions; restrictions to family visits, and school closures) were collected from 24 countries spanning five continents. The majority of the countries implemented multiple lockdowns with partial or full reopening. There was an overall decrease in active tuberculosis, drug-resistant tuberculosis, and latent tuberculosis cases. Although national lockdowns were effective in containing COVID-19 cases, several indicators of tuberculosis were affected during the pandemic.
- Published
- 2022
- Full Text
- View/download PDF
21. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study.
- Author
-
Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaquobi F, Blanc FX, Buonsenso D, Cho JG, Codecasa LR, Danila E, Duarte R, García-García JM, Gualano G, Rendon A, Silva DR, Souleymane MB, Tham SM, Thomas TA, Tiberi S, Udwadia ZF, Goletti D, Centis R, D'Ambrosio L, Sotgiu G, and Ong CWM
- Subjects
- Humans, Pandemics, SARS-CoV-2, COVID-19, Tuberculosis epidemiology, Tuberculosis therapy
- Abstract
Competing Interests: Conflict of interest: G.B. Migliori has nothing to disclose. Conflict of interest: P.M. Thong has nothing to disclose. Conflict of interest: J-W. Alffenaar has nothing to disclose. Conflict of interest: J. Denholm has nothing to disclose. Conflict of interest: M. Tadolini has nothing to disclose. Conflict of interest: F. Alyaquobi has nothing to disclose. Conflict of interest: F-X. Blanc has nothing to disclose. Conflict of interest: D. Buonsenso has nothing to disclose. Conflict of interest: J-G. Cho has nothing to disclose. Conflict of interest: L.R. Codecasa has nothing to disclose. Conflict of interest: E. Danila has nothing to disclose. Conflict of interest: R. Duarte has nothing to disclose. Conflict of interest: J-M. García-García has nothing to disclose. Conflict of interest: G. Gualano has nothing to disclose. Conflict of interest: A. Rendon has nothing to disclose. Conflict of interest: D.R. Silva has nothing to disclose. Conflict of interest: M.B. Souleymane has nothing to disclose. Conflict of interest: S.M. Tham has nothing to disclose. Conflict of interest: T.A. Thomas has nothing to disclose. Conflict of interest: S. Tiberi has nothing to disclose. Conflict of interest: Z.F. Udwadia has nothing to disclose. Conflict of interest: D. Goletti has nothing to disclose. Conflict of interest: R. Centis has nothing to disclose. Conflict of interest: L. D'Ambrosio has nothing to disclose. Conflict of interest: G. Sotgiu has nothing to disclose. Conflict of interest: C.W.M. Ong reports grants from National Medical Research Council (CSAINV17nov014), personal fees (young investigator award) from Institut Merieux, during the conduct of the study; other (honorarium) from Qiagen, outside the submitted work.
- Published
- 2021
- Full Text
- View/download PDF
22. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
- Author
-
Souleymane MB, Piubello A, Lawan IM, Hassane-Harouna S, Assao-Neino MM, Soumana A, Hamidou-Harouna Z, Gagara-Issoufou A, Ortuño-Gutiérrez N, Roggi A, Schwoebel V, Mamadou S, Lynen L, De Jong B, Van Deun A, and Decroo T
- Subjects
- Antitubercular Agents adverse effects, Humans, Linezolid adverse effects, Retrospective Studies, Rifampin adverse effects, Treatment Outcome, Deafness drug therapy, Hearing Loss chemically induced, Hearing Loss prevention & control, Ototoxicity, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
The short treatment regimen (STR) achieves a >80% cure in rifampicin-resistant tuberculosis (RR-TB) patients. However, ototoxicity induced by the injectable is a concern. This is the first study to evaluate the replacement of injectables by linezolid in patients with audiometry abnormalities at baseline or during the treatment.We conducted a retrospective cohort study of all RR-TB patients started on the STR between 2016 and June, 2019, in Niger. Patients underwent audiometry every 2 months in 2016 and every month since 2017.Of 195 patients, 16.9% (33 out of 195) received linezolid from the start (n=17), or switched from injectables to linezolid during treatment (n=16), based on audiometry abnormalities. In 2016, two patients developed severe ototoxicity despite switching to linezolid. Since 2017, no patient developed severe hearing loss or complete deafness. Severe haematological toxicity was observed in 18.1% (six out of 33) of patients on linezolid, none of which was life threatening. The use of linezolid was associated with severe but manageable adverse events (hazard ratio 8.9, 95% CI 2.5-31.5; p=0.001). A total of 90.9% (30 out of 33) of patients on a linezolid-containing STR were cured, and none experienced treatment failure. Three died, but not due to adverse events.Baseline and monthly audiometry monitoring and using linezolid after detection of hearing abnormalities appears effective to prevent severe ototoxicity, while keeping high treatment success and manageable adverse events., Competing Interests: Conflict of interest: M.B. Souleymane has nothing to disclose. Conflict of interest: A. Piubello has nothing to disclose. Conflict of interest: I.M. Mamane-Lawan has nothing to disclose. Conflict of interest: S. Hassane-Harouna has nothing to disclose. Conflict of interest: M.M. Assao-Neino has nothing to disclose. Conflict of interest: A. Soumana has nothing to disclose. Conflict of interest: Z. Hamidou-Harouna has nothing to disclose. Conflict of interest: A. Gagara-Issoufou has nothing to disclose. Conflict of interest: N. Ortuño-Gutiérez has nothing to disclose. Conflict of interest: A. Roggi has nothing to disclose. Conflict of interest: V. Schwoebel has nothing to disclose. Conflict of interest: S. Mamadou has nothing to disclose. Conflict of interest: L. Lynen has nothing to disclose. Conflict of interest: B. De Jong has nothing to disclose. Conflict of interest: A. Van Deun has nothing to disclose. Conflict of interest: T. Decroo has nothing to disclose., (Copyright ©ERS 2021.)
- Published
- 2021
- Full Text
- View/download PDF
23. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
- Author
-
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, and Ahmad Khan F
- Subjects
- Antitubercular Agents therapeutic use, Humans, Microbial Sensitivity Tests, Rifampin, Treatment Outcome, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9-12 months (the "shorter regimen") and individualised regimens of ≥20 months ("longer regimens").We collected individual patient data from observational studies identified through systematic reviews and a public call for data. We included patients meeting WHO eligibility criteria for the shorter regimen: not previously treated with second-line drugs, and with fluoroquinolone- and second-line injectable agent-susceptible RR/MDR-TB. We used propensity score matched, mixed effects meta-regression to calculate adjusted odds ratios and adjusted risk differences (aRDs) for failure or relapse, death within 12 months of treatment initiation and loss to follow-up.We included 2625 out of 3378 (77.7%) individuals from nine studies of shorter regimens and 2717 out of 13 104 (20.7%) individuals from 53 studies of longer regimens. Treatment success was higher with the shorter regimen than with longer regimens (pooled proportions 80.0% versus 75.3%), due to less loss to follow-up with the former (aRD -0.15, 95% CI -0.17- -0.12). The risk difference for failure or relapse was slightly higher with the shorter regimen overall (aRD 0.02, 95% CI 0-0.05) and greater in magnitude with baseline resistance to pyrazinamide (aRD 0.12, 95% CI 0.07-0.16), prothionamide/ethionamide (aRD 0.07, 95% CI -0.01-0.16) or ethambutol (aRD 0.09, 95% CI 0.04-0.13).In patients meeting WHO criteria for its use, the standardised shorter regimen was associated with substantially less loss to follow-up during treatment compared with individualised longer regimens and with more failure or relapse in the presence of resistance to component medications. Our findings support the need to improve access to reliable drug susceptibility testing., Competing Interests: Conflict of interest: S. Abidi has nothing to disclose. Conflict of interest: J. Achar has nothing to disclose. Conflict of interest: M.M. Assao Neino has nothing to disclose. Conflict of interest: D. Bang has nothing to disclose. Conflict of interest: A. Benedetti has nothing to disclose. Conflict of interest: S. Brode reports grants from Insmed and the Canadian Institutes for Health Research, personal fees for educational presentations from Boehringer Ingelheim and AstraZeneca, outside the submitted work. Conflict of interest: J.R. Campbell has nothing to disclose. Conflict of interest: E. Casas has nothing to disclose. Conflict of interest: F. Conradie has nothing to disclose. Conflict of interest: G. Dravniece has nothing to disclose. Conflict of interest: P. du Cros reports he was previously a member of the steering committee and protocol writing committee for the PRACTECAL randomised controlled trial of three novel 6-month MDR-TB regimens; and has undertaken a paid consultancy between TB Alliance and Burnet Institute to investigate applicability of the TB-Nix regimen (a novel short MDR-TB regimen) to Papua New Guinea. Conflict of interest: D. Falzon has nothing to disclose. Conflict of interest: E. Jaramillo has nothing to disclose. Conflict of interest: C. Kuaban has nothing to disclose. Conflict of interest: Z. Lan has nothing to disclose. Conflict of interest: C. Lange reports personal fees for lectures from Chiesi, Gilead, Janssen, Lucane, Novartis, Oxoid, Berlin-Chemie and Thermo Fisher, outside the submitted work. Conflict of interest: P.Z. Li has nothing to disclose. Conflict of interest: M. Makhmudova has nothing to disclose. Conflict of interest: A.K.J. Maug has nothing to disclose. Conflict of interest: D. Menzies has nothing to disclose. Conflict of interest: G.B. Migliori has nothing to disclose. Conflict of interest: A. Miller reports that The Eli Lilly Foundation MDR-TB Partnership provided partial salary support in 2015–2016 through a grant to Salmaan Keshavjee, Harvard Medical School, although none of the work in the current paper or analysis was supported through that mechanism; the grant also paid for travel to a meeting in July of 2016. Conflict of interest: B. Myrzaliev has nothing to disclose. Conflict of interest: N. Ndjeka has nothing to disclose. Conflict of interest: J. Noeske has nothing to disclose. Conflict of interest: N. Parpieva has nothing to disclose. Conflict of interest: A. Piubello has nothing to disclose. Conflict of interest: V. Schwoebel has nothing to disclose. Conflict of interest: W. Sikhondze has nothing to disclose. Conflict of interest: R. Singla has nothing to disclose. Conflict of interest: M.B. Souleymane has nothing to disclose. Conflict of interest: A. Trébucq has nothing to disclose. Conflict of interest: A. Van Deun has nothing to disclose. Conflict of interest: K. Viney has nothing to disclose. Conflict of interest: K. Weyer has nothing to disclose. Conflict of interest: B.J. Zhang has nothing to disclose. Conflict of interest: F. Ahmad Khan reports grants from the World Health Organization during the conduct of the study., (The content of this work is copyright of the authors or their employers. Design and branding are copyright ©ERS 2020.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.